FTH vs OCS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
FTH · Faeth Therapeutics$7.88 ▼ 9.32%
OCS · Oculis$7.06 ▼ 5.11%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- FTH -12.2%
- OCS -63.4%
Head to head
| Metric | FTH | OCS |
|---|---|---|
| Price | $7.88 | $7.06 |
| Change today | ▼ 9.32% | ▼ 5.11% |
| Market cap | $203.65M | $437.15M |
| Return, 3 months | -77.3% | -46.4% |
| Return, year to date | -26.1% | -64.6% |
| Return, 1 year | -9.6% | -63.3% |
| P/E (TTM) | – | – |
| P/B | 1.3 | 1.8 |
| P/E percentile vs own 5y | 92nd | 64th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -346.4% | -8.2% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -229.6% | -47.5% |
| Analyst target vs. price | +633.2% | +461.9% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 23 | 36 |
| 30-day volatility | 192.7% | 58.7% |
| Max drawdown, 1 year | -80.3% | -79.1% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- OCS is the largest of the group by market value.
- FTH has returned the most over the past year.
- OCS has been the calmest stock over the last 30 days.